SMITH & NEPHEW

Smith & Nephew's stock hit a 52-week low at $27.54 and fell 26.81% over the past year. In the second quarter the company reported revenue of $1.6 billion, missing the $1.64 billion estimate; growth in sports medicine and wound care was offset by weakness in US orthopedics and at SANTYL. Analysts including Morgan Stanley and JPMorgan downgraded the stock and cut price targets, while management's dividend continuity, a 2.15% dividend yield and generous share buybacks were cited as signals of confidence. » Mere på de.investing.com

Smith & Nephew is offering to repurchase its senior notes (coupon 2.032%) due October 14, 2030, for up to $250 million aggregate principal amount; $900 million of these securities are currently outstanding. A US Treasury (coupon 4.375%, maturing August 31, 2031) plus a fixed spread of 55 basis points serves as the reference; accepted notes will be retired. The aim is debt management and to extend average maturity; the offer is conditional on a planned, simultaneous issuance of new senior notes due 2036 generating sufficient gross proceeds. Consideration per $1,000 will be determined on September 15, 2026; the offer expires on September 15, 2026, and the expected settlement date is September 18, 2026; if oversubscribed, allocations will be made pro rata. » Mere på de.investing.com

Smith & Nephew’s share hit a new 52-week low of 28.55 USD, leaving the stock about 23.9% lower year-to-date. For the second quarter the company reported revenue of 1.6 billion USD, missing the 1.64 billion USD forecast; adjusted revenue rose 1.6%, reported revenue rose 2.8%. Weaknesses in sports medicine and wound care, a softer US orthopedics business and a disappointing performance from SANTYL weighed on the results. Several analysts cut their ratings and price targets, underscoring the cautious outlook and investor pressure. » Mere på de.investing.com

Smith+Nephew confirmed that chief financial officer John Rogers will resign on 30 September to take up a new role in the US; he has left the board with immediate effect. The company has begun the search for a successor and appointed Pierre Palassian as interim CFO. According to CEO Deepak Nath, Rogers served three years as CFO and contributed to implementing the 12‑point plan, improving financial performance and developing the RISE strategy. » Mere på de.investing.com

Smith & Nephew reported revenue of $1.6bn in Q2, $40m below consensus; organic revenue rose 1.6%. Operating profit, excluding M&A, increased 9% to $566m, and the operating margin widened to 18.3%. Management cut its guidance for organic revenue growth in 2026 to around 4%, but left profit and cash-flow targets unchanged. The weakness was mainly driven by the US orthopaedics business; the company is banking on product launches such as LANDMARK and TESSA for a recovery. Pre-market the stock fell about 4.3% to $30.76. » Mere på de.investing.com